Application for Self-Monitoring of Cardiovascular Risk
調査の概要
詳細な説明
The study will consist of two phases - an initial feasibility trial (Phase 1), followed by a randomized clinical trial (Phase 2). Once the Phase 1 trial is evaluated, Phase 2 will be implemented.
Phase 1 will consist of up to 35 participants to ensure that the software application is user-friendly, properly stores pertinent data, and has no technical glitches. All participants in Phase 1 will have access to the software application and will be asked to complete online questionnaires, at baseline and post cardiac rehab, to assess their quality of life and also their satisfaction with their care and the software application itself.
Phase 2 will consist of 65 participants. These participants will be randomized to either 1) Cardiac Rehab (CR) alone along with answering questionnaires regarding quality of life and satisfaction of care or 2) CR along with the software application and the quality of life, satisfaction of care and software application questionnaires. All participants (both Phase 1 and Phase 2) enrolled into the study will be status-post percutaneous coronary intervention (PCI). The potential participants will be asked to participate while still in the hospital and will be approached as soon as possible after agreeing to participate in CR,. The participants who enroll in Phase 2 will be randomized prior to discharge from the hospital.
All participants in Phase 1 and those in Phase 2 who randomize to the software application will be instructed on the use of either the desktop or smart-phone version of the software application. Baseline information, including participant name, date of birth, email address, and phone number, will be gathered from the participant at that time, and all characteristics will be entered by the participant and study coordinator into their own account in the application.
The study will follow all Phase 1 participants and those in Phase 2 who randomize to the software application for three months after hospital dismissal and evaluate the following:
- Weight/BMI, blood pressure, and heart rate
- Usual lab values already gathered for the participant such as lipids, Complete Blood Count (CBC), and HgbA1C
- Quality of life, disposition, and mood
- Participant compliance, satisfaction, and adherence to the application
- Re-hospitalizations, participants phone calls, and cost of care
During the second week of their CR an additional 30-60 minute educational session will be required so that the study coordinator can instruct the participant on the software application and how to use it.
We will also ask that participants "log in" to their online account at least 3-4 times weekly for important reminders, care tips, and educational materials. This will last the duration of their cardiac rehabilitation program (approximately 12 weeks). Specific examples of sections within the software application will pertain to medication adherence, diet, exercise, educational materials, and reviews of your medical profile.
Finally, we would ask that participants (all of Phase 1 and those who randomize to the software application in Phase 2) to complete online questionnaires, at baseline and post cardiac rehab. that assess their quality of life and also their satisfaction with their care and the software application itself. This will be used for both data purposes as well as in future improvements to the program. These individual surveys will take approximately 5 minutes to complete. Phase 2 study participants who do not randomize to the software application will be sent the quality of life and satisfaction of care questionnaires.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Recently underwent PCI.
- Are eligible for enrollment to the Cardiovascular Health Clinic (CVHC)
- Do not have any physical impediments to physical activity
- Do not have any impediments to physically attending the Mayo Clinic's CVHC
- They are willing to incorporate the software application into their CR
- They must have access to the internet
Exclusion Criteria:
- - They are unable or unwilling to enroll in CR
- They are unable to physically attend Mayo Clinic's CVHC CR Program
- They are unwilling to incorporate the Personal Health Assistant into their CR
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
他の:Self Monitoring of Software Application
log into self monitoring software application from a home computer.
Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
|
Computer Software application to track health progress after interventional surgery
|
介入なし:介入なし
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Percentage of subjects who completed all tasks in the application.
時間枠:Baseline to 3 months
|
These data will provide the best summary of usability of the application.
|
Baseline to 3 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
User-reported satisfaction with application.
時間枠:Baseline to 3 months
|
These data will provide additional insights into how users view the application interface and help us modify the design to enhance compliance.
|
Baseline to 3 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Body weight
時間枠:Baseline to 3 months
|
Weight will be the most sensitive indicator that completion of the tasks assigned in the application lead to subsequent behavioral chance and reduction of cardiovascular risk.
|
Baseline to 3 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Thomas G Allsion, PHD、Mayo Clinic
出版物と役立つリンク
一般刊行物
- Widmer RJ, Senecal C, Allison TG, Lopez-Jimenez F, Lerman LO, Lerman A. Dose-Response Effect of a Digital Health Intervention During Cardiac Rehabilitation: Subanalysis of Randomized Controlled Trial. J Med Internet Res. 2020 Feb 26;22(2):e13055. doi: 10.2196/13055.
- Widmer RJ, Allison TG, Lennon R, Lopez-Jimenez F, Lerman LO, Lerman A. Digital health intervention during cardiac rehabilitation: A randomized controlled trial. Am Heart J. 2017 Jun;188:65-72. doi: 10.1016/j.ahj.2017.02.016. Epub 2017 Feb 20.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
冠動脈疾患の臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ